Skip to main content
. 2017 May 23;8(45):79337–79346. doi: 10.18632/oncotarget.18107

Table 1. Baseline characteristics in patients with ENKTL.

Characteristics Total
(n = 100)
TN group
(n = 41)
No TN group
(n = 59)
p-value
Gender
 Male 77 (77.0) 29 (29.0) 48 (48.0) 0.541
 Female 23 (23.0) 12 (12.0) 11 (11.0)
Age (years)
 > 60 years 45 (45.0) 20 (20.0) 25 (25.0) 0.529
 ≤ 60 years 55 (55.0) 21 (21.0) 34 (34.0)
Regional nodal involvement
 Yes 31 (31.0) 16 (16.0) 15 (15.0) 0.150
 No 69 (69.0) 25 (25.0) 44 (44.0)
ECOG PS
 ≥ 2 12 (12.0) 8 (8.0) 4 (4.0) 0.049
 0-1 88 (88.0) 33 (33.0) 55 (55.0)
Serum LDH level
 High than normal 29 (29.0) 15 (15.0) 14 (14.0) 0.166
 Normal 71 (71.0) 26 (26.0) 45 (45.0)
B symptoms
 Yes 21 (21.0) 12 (12.0) 9 (9.0) 0.092
 No 79 (79.0) 29 (29.0) 50 (50.0)
IPI score
 0-2 91 (91.0) 35 (35.0) 56 (56.0) 0.102
 ≥ 3 9 (9.0) 6 (6.0) 3 (3.0)
Local tumor invasiveness
 Yes 22 (22.0) 10 (10.0) 12 (12.0) 0.630
 No 78 (78.0) 31 (31.0) 47 (47.0)
Korean prognostic Index (KPI)
 High KPI score ≥ 3 points 11 (11.0) 8 (8.0) 3 (3.0) 0.024
Glasgow prognostic score (GPS)
 High GPS (2 points) 31 (31.0) 17 (17.0) 14 (14.0) 0.061
CRP/albumin ratio (CAR)
 High CAR 22 (22.0) 15 (15.0) 7 (7.0) 0.003
SUVmax on PET/CT
 Median (range) 6.4 (2.9-22.3) 8.4 (2.9-21.1) 5.2 (3.1-22.3) 0.008
Metabolic tumor volume on PET/CT
 Median (range) 36.2 (5.1-1164.9) 84.5 (5.1-1164.9) 32.8 (6.2-337.0) <0.001
Treatment
Complete resection group 37 (37.0) 13 (13.0) 24 (24.0) 0.363
 CMT 8 (8.0) 3 (3.0) 5 (5.0) 0.399
 Chemotherapy only 29 (29.0) 10 (10.0) 19 (19.0)
Only biopsy group 63 (63.0) 28 (28.0) 35 (25.0) 0.363
 CMT 56 (56.0) 26 (26.0) 30 (30.0) 0.490
 Chemotherapy only 7 (7.0) 2 (2.0) 5 (5.0)

ECOG, Eastern Cooperative Oncology Group; PS, performance status; LDH, lactate dehydrogenase; IPI, International Prognostic Index; SUVmax, maximum standard uptake value; PET/CT, positron emission tomography; CT, computed tomography, CMT, combined modality treatment (concurrent chemoradiotherapy with chemotherapy)